Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis
AUTOR(ES)
Kaatz, Glenn W.
FONTE
American Society for Microbiology
RESUMO
Trovafloxacin is a new fluoronaphthyridone chemically and functionally related to members of the fluoroquinolone class of antimicrobial agents. The in vivo efficacy of the drug was compared with that of vancomycin by using the rabbit model of left-sided endocarditis. Rabbits infected with either a nafcillin-susceptible or -resistant test strain were treated with trovafloxacin (13.3 mg/kg of body weight every 12 h) or vancomycin (25 mg/kg of body weight every 8 h) for 4 days. In comparison with untreated controls, both antimicrobial agents effectively cleared bacteremia and significantly reduced bacterial counts in vegetations and tissues of animals infected with either test strain. No resistance to trovafloxacin emerged in test strains during therapy. We conclude that in this model trovafloxacin is as efficacious as vancomycin is and may serve as a viable alternative to vancomycin for use in humans with similar infections.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=105396Documentos Relacionados
- Comparative Efficacy of Trovafloxacin in Experimental Endocarditis Caused by Ciprofloxacin-Sensitive, Methicillin-Resistant Staphylococcus aureus
- Efficacy of LY333328 against Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis
- Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.
- Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
- Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus
